Pharmacological activation of sigma-1 receptor by clinically approved drugs enhances K V 1.5 channel activity in the pulmonary circulation.
文献摘要
Sigma-1 receptor (S1R) is a ligand-operated chaperone involved in the modulation of ion channel function, including the voltage-gated potassium (K V ) channels such as K V 1.5. K V 1.5 channel dysfunction is a characteristic feature of pulmonary arterial hypertension (PAH), and its pharmacological modulation represents an attractive strategy in this context. Here, we investigated whether pharmacological activation of S1R by clinically approved drugs, such as dimemorfan and fluoxetine, enhances K V 1.5 channel activity in pulmonary arterial smooth muscle cells (PASMCs). K V currents were recorded using whole-cell patch-clamp in freshly isolated PASMCs from rats, humans, and rats with experimental PAH induced by SU5416 plus hypoxia (SuHx). Pulmonary vascular reactivity was assessed was assessed in isolated pulmonary arteries using wire myography, and protein expression was analysed by Western blot. Dimemorfan and fluoxetine significantly increased DPO-1-sensitive K V currents, corresponding to the K V 1.5 component, without affecting DPO-1-insensitive currents. These effects were abolished by pharmacological blockade of S1R, supporting a S1R-dependent mechanism. Increased K V 1.5 activity was associated with reduced pulmonary vasoconstrictor responses. The K V 1.5-enhancing effects of both compounds were also observed in PASMCs from PAH rats. The ability of dimemorfan to enhance K V currents was also confirmed in freshly isolated human PASMCs. Overall, these findings support a role of S1R as a pharmacological regulator of K V 1.5 channel function and provide evidence that clinically approved S1R-active drugs can enhance K V 1.5 activity in pulmonary vascular smooth muscle. This pharmacological approach may provide a basis for further investigation of drug repurposing strategies targeting KV1.5 channel dysfunction in PAH.